Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Xvivo Perfusion AB's 14-Day RSI or its related term are showing as below:
CHIX:XVIVOs's 14-Day RSI is ranked better than 78.69% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 46
vs CHIX:XVIVOs: 91.71
Xvivo Perfusion AB (CHIX:XVIVOs) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Xvivo Perfusion AB 14-Day RSI Related Terms
CHIX:XVIVOS vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 14-Day RSI falls into.
Xvivo Perfusion AB (CHIX:XVIVOs) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (CHIX:XVIVOS) has a 14-Day RSI of 91.71 as of Jul. 20, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #185 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 21.3%.
Is Xvivo Perfusion AB's 14-Day RSI too high?
Xvivo Perfusion AB's current 14-Day RSI is 91.71. The Medical Devices & Instruments industry median 14-Day RSI is 46.00. Xvivo Perfusion AB's value of 91.71 is 99.4% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #185 out of 868 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #185 out of 868 companies for 14-Day RSI. This places Xvivo Perfusion AB in the top 21% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 46.00. Xvivo Perfusion AB's value of 91.71 is 99.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 46.00, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current 14-Day RSI of 91.71 is 99.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 46.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current 14-Day RSI is 91.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Xvivo Perfusion AB (CHIX:XVIVOS) has a current 14-Day RSI of 91.71. The stock's GF Value™ is kr504.43, compared to a current price of kr302.60 — trading 40% below its estimated fair value. The current 14-Day RSI is 91.71 and 99.4% above the Medical Devices & Instruments industry median of 46.00. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Xvivo Perfusion AB (CHIX:XVIVOS), the current 14-Day RSI is 91.71 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (CHIX:XVIVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of kr302.60 is trading 40% below its estimated GF Value™ of kr504.43.
Key valuation signals for CHIX:XVIVOS:
14-Day RSI: 91.71
GF Value™: kr504.43 vs. price of kr302.60 (40% below fair value)
Industry Position: 99.4% above the Medical Devices & Instruments median (#185 of 868)
No single metric tells the full story. See the CHIX:XVIVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for CHIX:XVIVOS
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:XVIVOS has been successfully added to your 
